AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27132450
Drug: Midazolam 1
RxNorm normalized name: midazolam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 1 μg x kg(‐1) x min(‐1) for sedation and 1 mg/mL remifentanil for analgesia
Trial: 20032543
Drug: 12-16 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-16 weeks of pegylated interferon and ribavirin treatment
Trial: 20032543
Drug: 24 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 weeks of pegylated interferon and ribavirin treatment
Trial: 12720508
Drug: Cold vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold vaccine (no deliberate warming)
Trial: 12720508
Drug: Warmed vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warmed vaccine (37 degrees C incubator)
Trial: 12720508
Drug: Rubbed vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rubbed vaccine (rubbed between palms for 1 minute)
Trial: 10934803
Drug: CEOV therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEOV therapy (cyclophosphamide, epirubicin, vincristine, etoposide)
Trial: 10934803
Drug: CEOV-CAM therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEOV-CAM therapy (cyclophosphamide, ACNU, methotrexate)
Trial: 10934803
Drug: CEOV-CAM therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEOV-CAM therapy (limited disease)
Trial: 10934803
Drug: CEOV therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEOV therapy (limited disease)
Trial: 8393760
Drug: Three injections
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three injections two weeks apart
Trial: 30900326
Drug: High-dose caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose caffeine citrate (80 mg/kg)
Trial: 30900326
Drug: Standard-dose caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose caffeine citrate (20 mg/kg)
Trial: 22341379
Drug: Neural tissue
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neural tissue management (education, manual therapy, and nerve gliding exercises in 4 treatments over 2 weeks)
Trial: 20347506
Drug: gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine 1000 mg/m(2) days 1 and 8 plus carboplatin AUC 5.5 day 1 (GCb)
Trial: 20347506
Drug: gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine 1000 mg/m(2) days 1 and 8 plus paclitaxel 200 mg/m(2) day 1 (GP)
Trial: 20347506
Drug: paclitaxel 225
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: paclitaxel 225 mg/m(2) plus carboplatin AUC 6.0 day 1 (PCb)
Trial: 20347506
Drug: Histology-by-treatment interaction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histology-by-treatment interaction effect between GCb and PCb
Trial: 10204826
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment control plus diet (C+D)
Trial: 7539233
Drug: High-dose danaparoid
RxNorm normalized name: DANAPAROID
DrugBank: Danaparoid (DB06754)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose danaparoid (intravenous loading dose of 2000 U followed by 2000 U administered subcutaneously twice daily)
Trial: 7539233
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (intravenous loading dose of 2500 U followed by dose-adjusted continuous infusion)
Trial: 7539233
Drug: High-dose danaparoid
RxNorm normalized name: DANAPAROID
DrugBank: Danaparoid (DB06754)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose danaparoid
Trial: 7539233
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (low-dose danaparoid, high-dose danaparoid, unfractionated heparin)
Trial: 31599059
Drug: Topical 2%
RxNorm normalized name: menthol topical 2% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2% ketoconazole cream
Trial: 6752876
Drug: Pirprofen (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirprofen (800 mg/day)
Trial: 373942
Drug: Aspirin (3,600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (3,600 mg/day)
Trial: 31627938
Drug: Approximately 1
RxNorm normalized name: (CYS74>SER,ALA245>THR)ADENOSINE DEAMINASE (BOS TAURUS, BOVINE)-(1-356)-PEPTIDE, PRODUCED IN ESCHERICHIA COLI, SUBSTITUTED ON N2 OF THE N-TERMINAL ALANYL RESIDUE (A1) AND ON N6 OF LYSYL RESIDUES (K) WITH AN AVERAGE OFAPPROXIMATELY 13 .OMEGA.-METHOXYPOLY(O
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 1 gram/day of purified fish oil containing 840 mg/day of EPA and docosahexaenoic acid (DHA)
Trial: 30766593
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion at 0.4mcg/kg/hr
Trial: 30766593
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion at 0.2mcg/kg/min
Trial: 26867000
Drug: Subjective stimulant-like
RxNorm normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjective stimulant-like effects
Trial: 26867000
Drug: Subjective sedative-like
RxNorm normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjective sedative-like effects
Trial: 23013107
Drug: Transcranial laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial laser therapy with the NeuroThera® Laser System
Trial: 23013107
Drug: Sham transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham transcranial laser therapy procedure
Trial: 22777879
Drug: Various obesity
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various obesity treatments (specific treatments not detailed)
Trial: 11899591
Drug: Alprazolam (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (0.25 mg) administered twice daily to the treated group
Trial: 7653806
Drug: Eltanolone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltanolone (0.5 mg/kg) + fentanyl (3 micrograms/kg)
Trial: 7653806
Drug: Thiopental (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental (3 mg/kg) + fentanyl (3 micrograms/kg)
Trial: 795564
Drug: Gonadotrophin releasing
RxNorm normalized name: Gonadotrophin releasing factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotrophin releasing hormone (500 mug subcutaneously every 8 h for 4 weeks)
Trial: 27883311
Drug: Higher optimism
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher optimism regarding the effects of HIV treatments on HIV transmission
Trial: 16425125
Drug: Single-dose nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose nevirapine plus zidovudine (SD-NVP + ZDV)
Trial: 16425125
Drug: Single-dose nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose nevirapine (SD-NVP) alone
Trial: 12830834
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine (ME)
Trial: 1650036
Drug: Selective decontamination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective decontamination of the digestive tract (SDD) with polymyxin, amphotericin, tobramycin, and intravenous cefotaxime
Trial: 10999057
Drug: Standard antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antibiotic therapy (Control)
Trial: 28455894
Drug: Community Treatment
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [Sanitizing Liquid for Community Support]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community Treatment Program (CTP)
Trial: 28455894
Drug: Individual Treatment
RxNorm normalized name: Alex Rubber Tip Individual Pack 3/4"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual Treatment Program (ITP)
Trial: 23701746
Drug: AV7909 Formulation
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AV7909 Formulation 1 (0.5 mL AVA + 0.5 mg CPG 7909)
Trial: 23701746
Drug: AV7909 Formulation
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AV7909 Formulation 2 (0.5 mL AVA + 0.25 mg CPG 7909)
Trial: 23701746
Drug: AV7909 Formulation
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AV7909 Formulation 3 (0.25 mL AVA + 0.5 mg CPG 7909)
Trial: 23701746
Drug: AV7909 Formulation
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AV7909 Formulation 4 (0.25 mL AVA + 0.25 mg CPG 7909)
Trial: 23701746
Drug: BioThrax (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BioThrax (0.5 mL)
Trial: 23701746
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo (0.5 mL)
Trial: 17364078
Drug: Therapies (Riquent,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapies (Riquent, belimumab, mycophenolate mofetil, dehydroepiandrosterone, oestrogen therapy, cholesterol-lowering diet)
Trial: 15206062
Drug: scIL-2 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scIL-2 at a dose of 1.5 mIU (n=36)
Trial: 15206062
Drug: scIL-2 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scIL-2 at a dose of 4.5 mIU (n=36)
Trial: 15206062
Drug: scIL-2 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scIL-2 at a dose of 7.5 mIU (n=37)
Trial: 12394945
Drug: Early high-volume
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early high-volume hemofiltration (72-96 L per 24 hrs)
Trial: 12394945
Drug: Early low-volume
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early low-volume hemofiltration (24-36 L per 24 hrs)
Trial: 12394945
Drug: Late low-volume
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late low-volume hemofiltration (24-36 L per 24 hrs)
Trial: 9891536
Drug: Combined chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chemotherapy (52 cases)
Trial: 2919938
Drug: Metered-dose inhaler
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered-dose inhaler (MDI) with a spacer
Trial: 26581079
Drug: Comparison with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison with psychosomatic and behavioral medicine journals
Trial: 11549097
Drug: Irbesartan 75
RxNorm normalized name: irbesartan 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 75 mg (oral capsule or intravenous infusion)
Trial: 8142265
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (FT + TAM 20 mg day‐1 for 2 years after DOX administration)
Trial: 8142265
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A (FT 50 mg day‐1 for 2 years after DOX administration)
Trial: 8142265
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (FT + TAM 20 mg day‐1 for 2 years)
Trial: 23672269
Drug: Flibanserin 100
RxNorm normalized name: flibanserin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flibanserin 100 mg once daily at bedtime (qhs)
Trial: 26356615
Drug: Cytoflavin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin (20 ml per day for 10 days)
Trial: 26356615
Drug: Cytoflavin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin (10 ml per day from 11th to 20th day)
Trial: 26356615
Drug: Cytoflavin (20-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin (20-day therapy)
Trial: 26356615
Drug: Cytoflavin (10-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin (10-day therapy)
Trial: 23496988
Drug: Improved oral
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved oral health care and a diet of increased consistency
Trial: 22127965
Drug: Continuous sequential
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous sequential estrogen plus progestin (n = 52)
Trial: 19851520
Drug: Parnaparin (3200,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parnaparin (3200, 4250, 6400, or 12800 IUaXa) administered subcutaneously once daily for 3 to 5 days to 6 months
Trial: 17384437
Drug: Tolvaptan 30
RxNorm normalized name: tolvaptan 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan 30 mg once per day (n = 2072)
Trial: 17384437
Drug: Tolvaptan 30
RxNorm normalized name: tolvaptan 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan 30 mg once per day
Trial: 8630518
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH 0.1 IU/kg body wt per day)
Trial: 1569442
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy (one cycle)
Trial: 29231300
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment group (flying needling therapy + clomiphene)
Trial: 29231300
Drug: Flying needling
RxNorm normalized name: house fly extract
DrugBank: Musca domestica (DB10688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flying needling therapy group
Trial: 29231300
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (clomiphene)
Trial: 29231300
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment group and Flying needling therapy group
Trial: 2506598
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg PO lorazepam
Trial: 28570966
Drug: Family‐focused therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family‐focused therapy for adolescents (FFT‐A) plus pharmacotherapy
Trial: 28570966
Drug: Brief psychoeducation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief psychoeducation (enhanced care, or EC) plus pharmacotherapy
Trial: 25644344
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein supplementation (27 g/supplement, twice daily)
Trial: 25644344
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein supplementation (26 g/supplement, twice daily)
Trial: 25644344
Drug: Carbohydrate supplementation
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate supplementation (25 g maltodextrin/supplement, twice daily)
Trial: 10828727
Drug: Ropinirole 0.5
RxNorm normalized name: ropinirole 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole 0.5 mg
Trial: 8251279
Drug: Tropisetron 5
RxNorm normalized name: tropisetron 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron 5 mg (Navoban)
Trial: 29864432
Drug: Dexamethasone 60
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 60 mg over 3 perioperative days
Trial: 25899914
Drug: Individualized loading
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized loading dose (LD) regimen of cholecalciferol, 50,000 IU twice a week, followed by a monthly maintenance dose of either 50,000 or 25,000 IU
Trial: 25899914
Drug: Daily dose
RxNorm normalized name: LENVIMA 8mg Daily Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose (DD) regimen of cholecalciferol, 800 IU daily for 26 weeks
Trial: 8575576
Drug: Tiotropium bromide
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiotropium bromide doses
Trial: 1827799
Drug: Acitretin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acitretin (50 mg/day) plus UVB therapy
Trial: 1827799
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus UVB therapy
Trial: 31587979
Drug: Core decompression
RxNorm normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Core decompression and PRP‐incorporated autologous granular bone grafting (treatment group)
Trial: 19164343
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg desloratadine
Trial: 23053062
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg desloratadine
Trial: 19564277
Drug: Amoxicillin (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (90 mg/kg) with potassium clavulanate (6.4 mg/kg)
Trial: 16303845
Drug: Metyrapone (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metyrapone (500 mg p.o. qid for 2 weeks)
Trial: 15518626
Drug: HMR 3339
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMR 3339 (other doses)
Trial: 2496577
Drug: Flunarizine 15
RxNorm normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine 15 mg daily
Trial: 21973
Drug: 6-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-valent pneumococcal vaccine
Trial: 21973
Drug: 12-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-valent pneumococcal vaccine
Trial: 7138751
Drug: Metoprolol SA
RxNorm normalized name: metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol SA 200 mg
Trial: 7138751
Drug: Metoprolol SR
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol SR 200 mg
Trial: 7138751
Drug: Conventional Metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Metoprolol 200 mg
Trial: 30424742
Drug: Complex intervention
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex intervention combining behavioural support, nicotine replacement therapy, and personalized feedback on home air quality
Trial: 26228466
Drug: Yoga intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoga intervention (90 min once weekly for 10 weeks)
Trial: 23176560
Drug: Monthly motivation
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly motivation feedback generated by clinicians (additional to treatment as usual)
Trial: 7789486
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of BAY u 3405 (TP receptor antagonist)
Trial: 7789486
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of BAY u 3405 (TP receptor antagonist)
Trial: 7789486
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of BAY u 3405 (TP receptor antagonist)
Trial: 2189866
Drug: Ketotifen (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (oral administration for 3 months)
Trial: 23324510
Drug: Weight-based dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based dosing of insulin glargine (0.5 units/kg)
Trial: 23324510
Drug: Percentage-based dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percentage-based dosing of insulin glargine (50% of TDI)
Trial: 26233335
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine (84 μg)
Trial: 26233335
Drug: Intravenous dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexmedetomidine (84 μg)
Trial: 9460345
Drug: Antibody-targeted therapies
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody-targeted therapies
Trial: 3440774
Drug: Single 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 1 g doses of cefonicid followed by ethanol challenges
Trial: 3440774
Drug: Three consecutive
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three consecutive 1 g doses of cefonicid given at 24 h intervals followed by ethanol challenge
Trial: 25964168
Drug: Live virus
RxNorm normalized name: rubella and mumps live virus vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live virus zoster vaccine (ZV)
Trial: 22956195
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate (reference compound)